Les complications incluent la métastase, la douleur chronique et des problèmes fonctionnels.
ComplicationsLéiomyosarcomeMétastase
#2
Le léiomyosarcome peut-il se propager ?
Oui, il peut se propager à d'autres organes, notamment les poumons et le foie.
MétastaseLéiomyosarcomePropagation
#3
Y a-t-il des risques liés aux traitements ?
Oui, les traitements peuvent entraîner des effets secondaires comme la fatigue et des nausées.
Effets secondairesLéiomyosarcomeTraitements
#4
Comment gérer la douleur liée au léiomyosarcome ?
La gestion de la douleur peut inclure des médicaments, la physiothérapie et des soins palliatifs.
Gestion de la douleurLéiomyosarcomeSoins palliatifs
#5
Le suivi post-traitement est-il crucial ?
Oui, un suivi régulier est essentiel pour surveiller les récidives et gérer les complications.
Suivi post-traitementLéiomyosarcomeRécidive
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les facteurs incluent l'exposition à des radiations, des produits chimiques et des antécédents familiaux.
Facteurs de risqueLéiomyosarcomeRadiations
#2
L'âge influence-t-il le risque de léiomyosarcome ?
Oui, le risque augmente généralement avec l'âge, touchant souvent les adultes d'âge moyen.
ÂgeLéiomyosarcomeRisque
#3
Les maladies génétiques sont-elles un facteur ?
Certaines maladies génétiques, comme le syndrome de Li-Fraumeni, augmentent le risque.
Maladies génétiquesLéiomyosarcomeSyndrome de Li-Fraumeni
#4
Le sexe joue-t-il un rôle dans le risque ?
Oui, les femmes sont légèrement plus susceptibles de développer un léiomyosarcome utérin.
SexeLéiomyosarcomeRisque
#5
L'obésité est-elle un facteur de risque ?
Oui, l'obésité peut être associée à un risque accru de certains types de sarcomes, y compris le léiomyosarcome.
ObésitéLéiomyosarcomeRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Léiomyosarcome : Questions médicales les plus fréquentes",
"headline": "Léiomyosarcome : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Léiomyosarcome : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-08",
"dateModified": "2025-03-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Léiomyosarcome"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sarcomes",
"url": "https://questionsmedicales.fr/mesh/D012509",
"about": {
"@type": "MedicalCondition",
"name": "Sarcomes",
"code": {
"@type": "MedicalCode",
"code": "D012509",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.450.795"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Léiomyosarcome",
"alternateName": "Leiomyosarcoma",
"code": {
"@type": "MedicalCode",
"code": "D007890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Emily Z Keung",
"url": "https://questionsmedicales.fr/author/Emily%20Z%20Keung",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA."
}
},
{
"@type": "Person",
"name": "Anupama Bahadur",
"url": "https://questionsmedicales.fr/author/Anupama%20Bahadur",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
},
{
"@type": "Person",
"name": "Rajlaxmi Mundhra",
"url": "https://questionsmedicales.fr/author/Rajlaxmi%20Mundhra",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
},
{
"@type": "Person",
"name": "Anoosha K Ravi",
"url": "https://questionsmedicales.fr/author/Anoosha%20K%20Ravi",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
},
{
"@type": "Person",
"name": "Poonam Gill",
"url": "https://questionsmedicales.fr/author/Poonam%20Gill",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Use of the Endoleak-to-Aortic Density Ratio to Distinguish Direct Endoleaks from Indirect Endoleaks after Endovascular Aortic Aneurysm Repair.",
"datePublished": "2023-07-06",
"url": "https://questionsmedicales.fr/article/37419280",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jvir.2023.06.039"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Novel Technique and Outcomes for Transcaval Endoleak Embolization.",
"datePublished": "2023-01-12",
"url": "https://questionsmedicales.fr/article/36641088",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.avsg.2023.01.013"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluation of the Effectiveness of Endovascular Treatment of Type 2 Endoleaks.",
"datePublished": "2022-07-22",
"url": "https://questionsmedicales.fr/article/35878699",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.avsg.2022.06.099"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Endovascular aortic repair of endoleaks : Diagnosis, treatment, and outcomes].",
"datePublished": "2022-06-23",
"url": "https://questionsmedicales.fr/article/35736998",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00117-022-01033-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "The impact of completion and follow-up endoleaks on survival, reintervention, and rupture.",
"datePublished": "2023-02-24",
"url": "https://questionsmedicales.fr/article/36841312",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jvs.2023.02.009"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du tissu conjonctif et des tissus mous",
"item": "https://questionsmedicales.fr/mesh/D018204"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sarcomes",
"item": "https://questionsmedicales.fr/mesh/D012509"
},
{
"@type": "ListItem",
"position": 6,
"name": "Léiomyosarcome",
"item": "https://questionsmedicales.fr/mesh/D007890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Léiomyosarcome - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Léiomyosarcome",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Léiomyosarcome",
"description": "Comment diagnostique-t-on un léiomyosarcome ?\nQuels examens d'imagerie sont utilisés ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels marqueurs tumoraux sont associés ?\nPeut-on confondre le léiomyosarcome avec d'autres tumeurs ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endoleak#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Léiomyosarcome",
"description": "Quels sont les symptômes courants du léiomyosarcome ?\nLe léiomyosarcome provoque-t-il une perte de poids ?\nPeut-on avoir des symptômes respiratoires ?\nLes symptômes varient-ils selon la localisation ?\nY a-t-il des symptômes spécifiques aux femmes ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endoleak#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Léiomyosarcome",
"description": "Peut-on prévenir le léiomyosarcome ?\nLes facteurs environnementaux jouent-ils un rôle ?\nY a-t-il des habitudes à éviter ?\nLes antécédents familiaux influencent-ils le risque ?\nLe suivi médical régulier est-il important ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endoleak#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Léiomyosarcome",
"description": "Quels traitements sont disponibles pour le léiomyosarcome ?\nLa chirurgie est-elle toujours nécessaire ?\nLa chimiothérapie est-elle efficace ?\nLa radiothérapie est-elle une option ?\nY a-t-il des traitements expérimentaux ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endoleak#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Léiomyosarcome",
"description": "Quelles complications peuvent survenir ?\nLe léiomyosarcome peut-il se propager ?\nY a-t-il des risques liés aux traitements ?\nComment gérer la douleur liée au léiomyosarcome ?\nLe suivi post-traitement est-il crucial ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endoleak#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Léiomyosarcome",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de léiomyosarcome ?\nLes maladies génétiques sont-elles un facteur ?\nLe sexe joue-t-il un rôle dans le risque ?\nL'obésité est-elle un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endoleak#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un léiomyosarcome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie médicale et la biopsie des tissus affectés."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les IRM et les tomodensitométries (CT) sont couramment utilisés pour visualiser la tumeur."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il une biopsie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une biopsie est essentielle pour confirmer la nature maligne de la tumeur."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont associés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de marqueurs spécifiques, mais des tests génétiques peuvent aider."
}
},
{
"@type": "Question",
"name": "Peut-on confondre le léiomyosarcome avec d'autres tumeurs ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être confondu avec d'autres sarcomes ou tumeurs musculaires."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants du léiomyosarcome ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs, des masses visibles et des troubles fonctionnels selon la localisation."
}
},
{
"@type": "Question",
"name": "Le léiomyosarcome provoque-t-il une perte de poids ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une perte de poids inexpliquée peut survenir en raison de la maladie avancée."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes respiratoires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, si la tumeur se développe dans les poumons, des symptômes respiratoires peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon la localisation ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent de l'emplacement de la tumeur dans le corps."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux femmes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes peuvent éprouver des symptômes liés à des tumeurs utérines, comme des saignements."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le léiomyosarcome ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un mode de vie sain peut aider."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains produits chimiques peut augmenter le risque de léiomyosarcome."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et l'exposition à des agents cancérigènes peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque de léiomyosarcome."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il important ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical régulier peut aider à détecter précocement des anomalies."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour le léiomyosarcome ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est souvent nécessaire pour retirer la tumeur, selon sa taille et son emplacement."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie peut être utilisée, mais son efficacité varie selon les cas."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle une option ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée pour traiter les tumeurs inopérables ou résiduelles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques peuvent proposer des traitements expérimentaux pour le léiomyosarcome."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la métastase, la douleur chronique et des problèmes fonctionnels."
}
},
{
"@type": "Question",
"name": "Le léiomyosarcome peut-il se propager ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut se propager à d'autres organes, notamment les poumons et le foie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques liés aux traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent entraîner des effets secondaires comme la fatigue et des nausées."
}
},
{
"@type": "Question",
"name": "Comment gérer la douleur liée au léiomyosarcome ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion de la douleur peut inclure des médicaments, la physiothérapie et des soins palliatifs."
}
},
{
"@type": "Question",
"name": "Le suivi post-traitement est-il crucial ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour surveiller les récidives et gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition à des radiations, des produits chimiques et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de léiomyosarcome ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente généralement avec l'âge, touchant souvent les adultes d'âge moyen."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques sont-elles un facteur ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques, comme le syndrome de Li-Fraumeni, augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes sont légèrement plus susceptibles de développer un léiomyosarcome utérin."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité peut être associée à un risque accru de certains types de sarcomes, y compris le léiomyosarcome."
}
}
]
}
]
}
To define criteria to distinguish direct (type 1 or 3) from indirect endoleaks (type 2) in the arterial phase of contrast-enhanced computed tomography (CT) scans in patients with abdominal aortic aneu...
This retrospective study was conducted from January 2009 to October 2020 and included consecutive patients treated endovascularly for a direct endoleak or an indirect endoleak associated with an enlar...
Contrast-enhanced CT scans from 71 patients (87% men), who presented with 87 endoleaks (44 indirect and 43 direct endoleaks), treated by endovascular techniques were analyzed. Using visual criteria, 5...
An endoleak-to-aortic density ratio of >0.77 in the arterial phase of contrast-enhanced CT could be a strong discriminant of a direct-type endoleak....
Strategies for embolization of type 2 endoleaks include translumbar, transgraft, transarterial, and transcaval approaches. The transcaval approach is limited by an inconsistent ability to access the a...
A retrospective review of all patients who underwent transcaval embolization (TCE) at a tertiary referral center. From March 2019 to June 2021, 12 patients were identified to have undergone a novel ap...
Twelve patients underwent transcaval embolization using this method over the 3-year period. The average patient age was 79.2 ± 6.2 years and 10/12 (83.3%) were male. A high rate of comorbidities was n...
TCE is an adjunctive technique to treat endoleaks in patients who have either failed transarterial or translumbar access. An electrified 0.014″ chronic total occlusion wire technique for transcaval ac...
Endovascular abdominal aortic aneurysm repair (EVAR) is a safe and minimally invasive alternative to open surgical repair for infra renal aortic aneuvrysm. EVAR requires lifelong post-procedural surve...
A single center cohort of patients treated for EL2 with endovascular technique between 1998 and 2018 was formed to perform a descriptive analysis. Preoperative sizing, risk factors of endoleaks and in...
Six hundred seven patients underwent an endovascular treatment for abdominal aorta aneurysm between 1998 and 2018. One hundred forty-five type 2 endoleaks occurred during this period. Nineteen patient...
Long term clinical recurrence of type 2 endoleaks treated by endovascular procedures appear to be frequent in our experience, leading to several deaths and requiring open surgical treatment....
All patients who underwent endovascular aortic repair (EVAR) need a thorough follow-up, at least yearly. Contrast-enhanced ultrasound and computed tomography angiography (CTA) are the most important m...
Endoleaks may be seen at case completion of endovascular abdominal aortic aneurysm repair (EVAR), and the presence of an endoleak may impact outcomes. However, the clinical implications of various end...
We reviewed patients who underwent EVAR from 2003 to 2016 within the Vascular Quality Initiative-Medicare database and identified patients with endoleak at procedure completion and during follow-up, e...
Of 21,745 patients with completion endoleak data, 5085 (23%) had an endoleak. Compared with those without endoleak, those with type I endoleaks had lower 5-year survival (69% vs 75%; P < .001), type I...
Compared with patients with no endoleak, those with type I completion endoleaks have lower 5-year survival and freedom from reintervention. Patients with types I and III follow-up endoleaks also have ...
Thoracic endovascular aortic repair is commonly used in the surgical treatment of patients with aortic coarctation, but complications such as endoleaks can occur. This video tutorial presents a case s...
To assess the performance of dynamic or 4D CT in characterizing endoleaks in advanced endovascular aortic repair (branched and fenestrated) when other modalities fail to fully characterize the leak, m...
Retrospective review of 13 patients from 2008 to 2021 who underwent 16 4D CTs to characterize endoleaks in branched and fenestrated endovascular aortic repair (FB-EVAR). The 4D CTs were performed cove...
Overall sensitivity in 16 scans for endoleak detection was 100%. There was a specificity of 87.5% for determining the type of endoleak (14/16). These results included two studies that were inconclusiv...
4D CT is a useful adjunctive tool in FB-EVAR surveillance with excellent sensitivity and specificity in characterizing endoleaks. This allows for accurate localization of leaks, which is critical for ...
We present a rare case of short-segment jejunal infarction following inferior mesenteric artery embolisation for type 2 endoleak in a patient who previously underwent endovascular repair of abdominal ...
The objective of this study was to investigate the mid-term outcomes of embolization procedures for type II endoleak after endovascular abdominal aortic repair, and clarify the risk factors for aneury...
This was a retrospective multicenter registry study enrolling patients who underwent embolization procedures for type II endoleaks after EVAR from January 2012 to December 2018 at 19 Japanese centers....
A total of 315 patients (248 men and 67 women) were enrolled. The average duration from the initial embolization procedure to the last follow-up was 31.6 ± 24.6 months. The rates of freedom from aneur...
The embolization procedures were generally ineffective in preventing further expansion of abdominal aortic aneurysms in patients with type II endoleaks after EVAR, especially in patients with a large ...
Endovascular stent-graft therapy is a commonly performed procedure for aortic lesions worldwide and complications unique to stent grafts, such as postoperative endoleaks, are well known. However, as t...